Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy
Annelies Verbiest(KU Leuven), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Steven Joniau, Eduard Roussel, Annouschka Laenen(Statistics Belgium), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Lorenzo Tosco(KU Leuven), Maarten Albersen, Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 4
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504